Delivering on the promise of personalized healthcare

被引:10
作者
March, Ruth [1 ]
机构
[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England
关键词
biomarker; clinical development; diagnostics; partnership; personalized healthcare; regulatory assessment; CELL LUNG-CANCER; PREVIOUSLY TREATED PATIENTS; CLINICAL-TRIAL DESIGNS; TYROSINE KINASE; BREAST-CANCER; PHARMACOGENETICS; GEFITINIB; VALIDATION; STRATEGIES; INHIBITOR;
D O I
10.2217/PME.10.17
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Personalized healthcare (PHC) aims to deliver the right medicine, to the right patient, at the right dose and time, and has the potential to benefit everyone in the healthcare system. Delivering the promise of PHC depends on overcoming key challenges (e.g., identifying biomarkers or disease segmentation tools, facilitating partnerships, clinical development, regulatory engagement and market access) in an integrated fashion. Despite this, progress in PHC has been accelerating over the last few years and is now at a turning point. Flexibility from all those involved in PHC, including the pharmaceutical and diagnostic industries, health authorities and payers, will be required to ensure that the field comes to maturity and delivers its potential to improve patients' lives.
引用
收藏
页码:327 / 337
页数:11
相关论文
共 51 条
  • [1] Is personalized medicine finally arriving?
    Allison, Malorye
    [J]. NATURE BIOTECHNOLOGY, 2008, 26 (05) : 509 - 517
  • [2] Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective
    Amur, Shashi
    Frueh, Felix W.
    Lesko, Lawrence J.
    Huang, Shiew-Mei
    [J]. BIOMARKERS IN MEDICINE, 2008, 2 (03) : 305 - 311
  • [3] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
    Atkinson, AJ
    Colburn, WA
    DeGruttola, VG
    DeMets, DL
    Downing, GJ
    Hoth, DF
    Oates, JA
    Peck, CC
    Schooley, RT
    Spilker, BA
    Woodcock, J
    Zeger, SL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95
  • [4] BASERGA A, 1973, BIOMEDICINE, V18, P89
  • [5] Recommendations from the EGAPP Working Group: can tumor gene expression in patients with breast cancer?
    Berg, Alfred O.
    Grp, E. G. A. P. P. Working
    Armstrong, Katrina
    Botkin, Jeffrey
    Calonge, Ned
    Haddow, James
    Hayes, Maxine
    Kaye, Celia
    Phillips, Kathryn A.
    Piper, Margaret
    Richards, Carolyn Sue
    Scott, Joan A.
    Strickland, Ora L.
    Teutsch, Steven
    [J]. GENETICS IN MEDICINE, 2009, 11 (01) : 66 - 73
  • [6] Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors
    Bonomi, Philip D.
    Buckingham, Lela
    Coon, John
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4606S - 4612S
  • [7] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    Bryant, HE
    Schultz, N
    Thomas, HD
    Parker, KM
    Flower, D
    Lopez, E
    Kyle, S
    Meuth, M
    Curtin, NJ
    Helleday, T
    [J]. NATURE, 2005, 434 (7035) : 913 - 917
  • [8] Towards validation of statistically reliable biomarkers
    Buyse, Marc
    [J]. EJC SUPPLEMENTS, 2007, 5 (05): : 89 - 95
  • [9] OUTLOOK The microeconomics of personalized medicine: today's challenge and tomorrow's promise
    Davis, Jerel C.
    Furstenthal, Laura
    Desai, Amar A.
    Norris, Troy
    Sutaria, Saumya
    Fleming, Edd
    Ma, Philip
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (04) : 279 - 286
  • [10] *DEL CTR HLTH SOL, 2009, ROI TARG THER STRAT